Search research articles
Contact Us
Filters
Showing results (201-210 of 209) with videos related to
Page
of 21
Sort By:
You have reached the last page of results.
This site can display upto 209 results.
Revista Espanola De Cardiologia
|
August 10, 1999
[Changes in hospital mortality from acute myocardial infarction during the last 15 years. The impact of reperfusion treatments]
I Echanove Errazti, J A Velasco Rami, F Ridocci Soriano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 8, 2010
First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study
M L García de Paredes, F Del Moral González, P Martínez Del Prado, et al.
Medicina Intensiva
|
September 23, 2019
Interhospital Sepsis Code in Catalonia (Spain): Territorial model for initial care of patients with sepsis
J C Yébenes, C Lorencio, E Esteban, et al.
ESMO Open
|
April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
E Grande, T Alonso-Gordoa, O Reig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
R J Motzer, L Albiges, S A Treviño Aguirre, et al.
British Journal of Cancer
|
June 27, 2013
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
A Alcaraz, R González-López, J Morote, et al.
Alzheimer'S Research & Therapy
|
August 18, 2021
Combination of white matter hyperintensities and Aβ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort
G Ortega, A Espinosa, M Alegret, et al.
British Journal of Cancer
|
June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
C de la Piedra, A Alcaraz, J Bellmunt, et al.
Page
of 21
Search research articles
Search
Showing results (201-210 of 209) with videos related to
Sort By:
Page
of 21
You have reached the last page of results.
This site can display upto 209 results.
Revista Espanola De Cardiologia
|
August 10, 1999
[Changes in hospital mortality from acute myocardial infarction during the last 15 years. The impact of reperfusion treatments]
I Echanove Errazti, J A Velasco Rami, F Ridocci Soriano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 8, 2010
First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study
M L García de Paredes, F Del Moral González, P Martínez Del Prado, et al.
Medicina Intensiva
|
September 23, 2019
Interhospital Sepsis Code in Catalonia (Spain): Territorial model for initial care of patients with sepsis
J C Yébenes, C Lorencio, E Esteban, et al.
ESMO Open
|
April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
E Grande, T Alonso-Gordoa, O Reig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
R J Motzer, L Albiges, S A Treviño Aguirre, et al.
British Journal of Cancer
|
June 27, 2013
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
A Alcaraz, R González-López, J Morote, et al.
Alzheimer'S Research & Therapy
|
August 18, 2021
Combination of white matter hyperintensities and Aβ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort
G Ortega, A Espinosa, M Alegret, et al.
British Journal of Cancer
|
June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
C de la Piedra, A Alcaraz, J Bellmunt, et al.
Page
of 21